Page last updated: 2024-12-06
romazarit
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
ID Source | ID |
---|---|
PubMed CID | 71321 |
CHEMBL ID | 165090 |
SCHEMBL ID | 43265 |
MeSH ID | M0175329 |
Synonyms (39)
Synonym |
---|
D05751 |
109543-76-2 |
romazarit (usan/inn) |
romazarit |
NCGC00160541-01 |
ro 31-3948/000 |
2-[[2-(4-chlorophenyl)-4-methyl-1,3-oxazol-5-yl]methoxy]-2-methylpropanoic acid |
2-[[2-(4-chlorophenyl)-4-methyloxazol-5-yl]methoxy]-2-methylpropanoic acid |
CHEMBL165090 |
ro-313948000 |
dtxcid4026216 |
cas-109543-76-2 |
tox21_111884 |
dtxsid6046216 , |
romazaritum [inn-latin] |
propanoic acid, 2-((2-(4-chlorophenyl)-4-methyl-5-oxazolyl)methoxy)-2-methyl- |
romazarite [inn-french] |
romazarite |
cn68e94r2x , |
unii-cn68e94r2x |
2-((2-(p-chlorophenyl)-4-methyl-5-oxazolyl)methoxy)-2-methylpropionic acid |
romazaritum |
romazarit [usan:inn:ban] |
SCHEMBL43265 |
tox21_111884_1 |
NCGC00160541-02 |
romazarit [inn] |
ro-31-3948/000 |
romazarit [usan] |
2-[[2-(4-chlorophenyl)-4 -methyl-5-oxazolyl]methoxy]-2-methylpropionic acid |
LNXXSBRGLBOASF-UHFFFAOYSA-N |
2-[[2-(4-chlorophenyl)-4-methyl-5-oxazolyl]methoxy]-2-methylpropionic acid |
ro 31-3948; ro 31-3948/000 |
sr-01000385718 |
SR-01000385718-1 |
2-((2-(4-chlorophenyl)-4-methyloxazol-5-yl)methoxy)-2-methylpropanoic acid |
bdbm50229181 |
Q27275551 |
AKOS040747417 |
Research Excerpts
Overview
Romazarit is a new drug for which animal pharmacology suggests a disease-modifying action in rheumatoid arthritis (RA)
Excerpt | Reference | Relevance |
---|---|---|
"Romazarit is a new drug for which animal pharmacology suggests a disease-modifying action in rheumatoid arthritis (RA). " | ( A pharmacokinetic and tolerance study of romazarit in patients with rheumatoid arthritis. Bentley, J; Bird, HA; Helliwell, PS; Minty, S; Muirhead, GJ; Williams, PE; York, A, 1992) | 1.99 |
Pharmacokinetics
Excerpt | Reference | Relevance |
---|---|---|
" Therefore, a pharmacokinetic study was designed to estimate the dosage required to achieve these concentrations in man." | ( A pharmacokinetic and tolerance study of romazarit in patients with rheumatoid arthritis. Bentley, J; Bird, HA; Helliwell, PS; Minty, S; Muirhead, GJ; Williams, PE; York, A, 1992) | 0.55 |
" Model-independent pharmacokinetic analyses showed that romazarit was rapidly and extensively absorbed in a dose-proportional manner." | ( Pharmacokinetics and tolerance of romazarit after oral administration of ascending single doses to healthy human volunteers. Lücker, P; Muirhead, GJ; Williams, PE; Worth, E; Zimmer, R, ) | 0.66 |
Bioavailability
Excerpt | Reference | Relevance |
---|---|---|
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" Therefore, a pharmacokinetic study was designed to estimate the dosage required to achieve these concentrations in man." | ( A pharmacokinetic and tolerance study of romazarit in patients with rheumatoid arthritis. Bentley, J; Bird, HA; Helliwell, PS; Minty, S; Muirhead, GJ; Williams, PE; York, A, 1992) | 0.55 |
" At each dosage 9 volunteers were studied, of whom 6 received romazarit and 3 received placebo capsules in a double-blind manner." | ( Pharmacokinetics and tolerance of romazarit after oral administration of ascending single doses to healthy human volunteers. Lücker, P; Muirhead, GJ; Williams, PE; Worth, E; Zimmer, R, ) | 0.65 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (7)
Potency Measurements
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
AR protein | Homo sapiens (human) | Potency | 15.0890 | 0.0002 | 21.2231 | 8,912.5098 | AID743036 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 13.6726 | 0.0002 | 29.3054 | 16,493.5996 | AID743069; AID743075; AID743079 |
peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 21.3138 | 0.0010 | 19.4141 | 70.9645 | AID743140 |
activating transcription factor 6 | Homo sapiens (human) | Potency | 11.9856 | 0.1434 | 27.6121 | 59.8106 | AID1159516 |
peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 0.4053 | 0.0056 | 12.3677 | 36.1254 | AID624032 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Inhibition Measurements
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Prostaglandin G/H synthase 1 | Homo sapiens (human) | IC50 (µMol) | 6,500.0000 | 0.0002 | 1.5574 | 10.0000 | AID226126 |
Prostaglandin G/H synthase 2 | Homo sapiens (human) | IC50 (µMol) | 6,500.0000 | 0.0001 | 0.9950 | 10.0000 | AID226126 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Biological Processes (60)
Molecular Functions (8)
Ceullar Components (13)
Bioassays (64)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
AID226124 | Inhibition of prostaglandin synthetase in rat renal medulla | 1991 | Journal of medicinal chemistry, Feb, Volume: 34, Issue:2 | Romazarit: a potential disease-modifying antirheumatic drug. |
AID225402 | Plasma level in type II collagen arthritis model after 14 days of dosing at 20 mg/kg. | 1991 | Journal of medicinal chemistry, Feb, Volume: 34, Issue:2 | Romazarit: a potential disease-modifying antirheumatic drug. |
AID186271 | Radiographic change was judged in the area of the talus joint, using an arbitrary scoring system upon termination of the test (14 days dosing of 40 mg/kg)in a model of type II collagen arthritis in the rat. | 1991 | Journal of medicinal chemistry, Feb, Volume: 34, Issue:2 | Romazarit: a potential disease-modifying antirheumatic drug. |
AID225404 | Plasma level in type II collagen arthritis model after 14 days of dosing at 60 mg/kg. | 1991 | Journal of medicinal chemistry, Feb, Volume: 34, Issue:2 | Romazarit: a potential disease-modifying antirheumatic drug. |
AID225401 | Plasma level in type II collagen arthritis model after 14 days of dosing at 100 mg/kg. | 1991 | Journal of medicinal chemistry, Feb, Volume: 34, Issue:2 | Romazarit: a potential disease-modifying antirheumatic drug. |
AID181831 | Compound was evaluated in developing adjuvant arthritis model rats for its effect on paw edema. | 1991 | Journal of medicinal chemistry, Feb, Volume: 34, Issue:2 | Romazarit: a potential disease-modifying antirheumatic drug. |
AID221141 | Haemoglobin level determined in rat type II collagen arthritis model after 14 days dosing of 40 mg/kg. | 1991 | Journal of medicinal chemistry, Feb, Volume: 34, Issue:2 | Romazarit: a potential disease-modifying antirheumatic drug. |
AID172372 | Hepatic effect assessed by increase in liver weight after 14 days of dosing at 100 mg/kg orally. | 1991 | Journal of medicinal chemistry, Feb, Volume: 34, Issue:2 | Romazarit: a potential disease-modifying antirheumatic drug. |
AID186281 | Radiographic change was judged in the area of the tarsus region, using an arbitrary scoring system upon termination of the test (14 days dosing of 60 mg/kg)in a model of type II collagen arthritis in the rat. | 1991 | Journal of medicinal chemistry, Feb, Volume: 34, Issue:2 | Romazarit: a potential disease-modifying antirheumatic drug. |
AID221953 | Inhibition of human PGE-2 production. | 1991 | Journal of medicinal chemistry, Feb, Volume: 34, Issue:2 | Romazarit: a potential disease-modifying antirheumatic drug. |
AID23477 | Partition coefficient (logP) | 1991 | Journal of medicinal chemistry, Feb, Volume: 34, Issue:2 | Romazarit: a potential disease-modifying antirheumatic drug. |
AID186270 | Radiographic change was judged in the area of the talus joint, using an arbitrary scoring system upon termination of the test (14 days dosing of 20 mg/kg)in a model of type II collagen arthritis in the rat. | 1991 | Journal of medicinal chemistry, Feb, Volume: 34, Issue:2 | Romazarit: a potential disease-modifying antirheumatic drug. |
AID221139 | Haemoglobin level determined in rat type II collagen arthritis model after 14 days dosing of 100 mg/kg. | 1991 | Journal of medicinal chemistry, Feb, Volume: 34, Issue:2 | Romazarit: a potential disease-modifying antirheumatic drug. |
AID186279 | Radiographic change was judged in the area of the tarsus region, using an arbitrary scoring system upon termination of the test (14 days dosing of 40 mg/kg)in a model of type II collagen arthritis in the rat. | 1991 | Journal of medicinal chemistry, Feb, Volume: 34, Issue:2 | Romazarit: a potential disease-modifying antirheumatic drug. |
AID172375 | Hepatic effect assessed by increase in liver weight after 14 days of dosing at 40 mg/kg orally. | 1991 | Journal of medicinal chemistry, Feb, Volume: 34, Issue:2 | Romazarit: a potential disease-modifying antirheumatic drug. |
AID186275 | Radiographic change was judged in the area of the tarsus region, using an arbitrary scoring system upon termination of the test (14 days dosing of 100 mg/kg)in a model of type II collagen arthritis in the rat. | 1991 | Journal of medicinal chemistry, Feb, Volume: 34, Issue:2 | Romazarit: a potential disease-modifying antirheumatic drug. |
AID172368 | Hepatic effect assessed by increase in catalase levels after 14 days of dosing at 40 mg/kg orally. | 1991 | Journal of medicinal chemistry, Feb, Volume: 34, Issue:2 | Romazarit: a potential disease-modifying antirheumatic drug. |
AID172370 | Hepatic effect assessed by increase in catalase levels after 14 days of dosing at 60 mg/kg orally. | 1991 | Journal of medicinal chemistry, Feb, Volume: 34, Issue:2 | Romazarit: a potential disease-modifying antirheumatic drug. |
AID172367 | Hepatic effect assessed by increase in catalase levels after 14 days of dosing at 20 mg/kg orally. | 1991 | Journal of medicinal chemistry, Feb, Volume: 34, Issue:2 | Romazarit: a potential disease-modifying antirheumatic drug. |
AID186278 | Radiographic change was judged in the area of the tarsus region, using an arbitrary scoring system upon termination of the test (14 days dosing of 20 mg/kg)in a model of type II collagen arthritis in the rat. | 1991 | Journal of medicinal chemistry, Feb, Volume: 34, Issue:2 | Romazarit: a potential disease-modifying antirheumatic drug. |
AID173701 | Percent decrease in serum haemoglobin evaluated in a developing adjuvant arthritis model rats. | 1991 | Journal of medicinal chemistry, Feb, Volume: 34, Issue:2 | Romazarit: a potential disease-modifying antirheumatic drug. |
AID225403 | Plasma level in type II collagen arthritis model after 14 days of dosing at 40 mg/kg. | 1991 | Journal of medicinal chemistry, Feb, Volume: 34, Issue:2 | Romazarit: a potential disease-modifying antirheumatic drug. |
AID172365 | Hepatic effect assessed by increase in catalase levels after 14 days of dosing at 100 mg/kg orally. | 1991 | Journal of medicinal chemistry, Feb, Volume: 34, Issue:2 | Romazarit: a potential disease-modifying antirheumatic drug. |
AID226126 | Inhibition of prostaglandin synthetase in sheep seminal vesicle | 1991 | Journal of medicinal chemistry, Feb, Volume: 34, Issue:2 | Romazarit: a potential disease-modifying antirheumatic drug. |
AID186273 | Radiographic change was judged in the area of the talus joint, using an arbitrary scoring system upon termination of the test (14 days dosing of 60 mg/kg)in a model of type II collagen arthritis in the rat. | 1991 | Journal of medicinal chemistry, Feb, Volume: 34, Issue:2 | Romazarit: a potential disease-modifying antirheumatic drug. |
AID172377 | Hepatic effect assessed by increase in liver weight after 14 days of dosing at 60 mg/kg orally. | 1991 | Journal of medicinal chemistry, Feb, Volume: 34, Issue:2 | Romazarit: a potential disease-modifying antirheumatic drug. |
AID221142 | Haemoglobin level determined in rat type II collagen arthritis model after 14 days dosing of 60 mg/kg. | 1991 | Journal of medicinal chemistry, Feb, Volume: 34, Issue:2 | Romazarit: a potential disease-modifying antirheumatic drug. |
AID186125 | Radiographic change was judged in the area of the talus joint, using an arbitrary scoring system upon termination of the test (14 days dosing of 100 mg/kg)in a model of type II collagen arthritis in the rat. | 1991 | Journal of medicinal chemistry, Feb, Volume: 34, Issue:2 | Romazarit: a potential disease-modifying antirheumatic drug. |
AID221140 | Haemoglobin level determined in rat type II collagen arthritis model after 14 days dosing of 20 mg/kg. | 1991 | Journal of medicinal chemistry, Feb, Volume: 34, Issue:2 | Romazarit: a potential disease-modifying antirheumatic drug. |
AID172374 | Hepatic effect assessed by increase in liver weight after 14 days of dosing at 20 mg/kg orally. | 1991 | Journal of medicinal chemistry, Feb, Volume: 34, Issue:2 | Romazarit: a potential disease-modifying antirheumatic drug. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (16)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 4 (25.00) | 18.2507 |
2000's | 2 (12.50) | 29.6817 |
2010's | 4 (25.00) | 24.3611 |
2020's | 6 (37.50) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.01
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.01) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 3 (17.65%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 14 (82.35%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |